Abstract：
BACKGROUND: Managing psoriasis (PsO) and its comorbidities, particularly psoriatic arthritis, often involves using interleukin (IL)-23 and IL-12/23 inhibitors. However, the comparative risk of these treatments still needs to be explored.
OBJECTIVE: This study evaluates the risk of developing psoriatic arthritis in patients treated with IL-23 inhibitors compared to IL-12/23 inhibitors.
METHODS: This retrospective cohort study utilized data from the TriNetX, including adult patients diagnosed with PsO. Patients with IL-23 or IL-12/23 inhibitors treatment were included and propensity score matched. The primary outcome was the incidence of psoriatic arthritis (PsA), analyzed using a Cox regression hazard model and Kaplan-Meier estimates.
RESULTS: The study included matched cohorts of patients treated with IL-23 inhibitors (n = 2273) and IL-12/23 inhibitors (n = 2995). Cox regression analysis revealed no significant difference in the cumulative incidence of PsA between the IL-23i and IL-12/23i cohorts (P = .812). Kaplan-Meier estimates confirmed similar cumulative incidences of arthropathic PsO in both cohorts over the study period.
CONCLUSIONS: Long-term follow-up studies are required to understand more of the effects of these interleukin inhibitors.
CONCLUSIONS: No significant difference but a numerically lower risk of psoriatic arthritis in PsO patients treated with IL-23 inhibitors than with IL-12/23 inhibitors was found, underscoring their comparable efficacy in PsO management and follow-up.
OBJECTIVE: This study evaluates the risk of developing psoriatic arthritis in patients treated with IL-23 inhibitors compared to IL-12/23 inhibitors.
METHODS: This retrospective cohort study utilized data from the TriNetX, including adult patients diagnosed with PsO. Patients with IL-23 or IL-12/23 inhibitors treatment were included and propensity score matched. The primary outcome was the incidence of psoriatic arthritis (PsA), analyzed using a Cox regression hazard model and Kaplan-Meier estimates.
RESULTS: The study included matched cohorts of patients treated with IL-23 inhibitors (n = 2273) and IL-12/23 inhibitors (n = 2995). Cox regression analysis revealed no significant difference in the cumulative incidence of PsA between the IL-23i and IL-12/23i cohorts (P = .812). Kaplan-Meier estimates confirmed similar cumulative incidences of arthropathic PsO in both cohorts over the study period.
CONCLUSIONS: Long-term follow-up studies are required to understand more of the effects of these interleukin inhibitors.
CONCLUSIONS: No significant difference but a numerically lower risk of psoriatic arthritis in PsO patients treated with IL-23 inhibitors than with IL-12/23 inhibitors was found, underscoring their comparable efficacy in PsO management and follow-up.
摘要：
背景：治疗银屑病及其合并症，尤其是银屑病关节炎,通常涉及使用IL-23和IL-12/23抑制剂。然而,这些治疗的相对风险仍需探讨.
目的：本研究评估了与IL-12/23抑制剂相比，使用IL23抑制剂治疗的患者发生银屑病关节炎的风险。
方法：这项回顾性队列研究利用了TriNetX的数据，包括被诊断为牛皮癣的成年患者。包括使用IL-23或IL-12/23抑制剂治疗的患者并且倾向评分匹配。主要结果是关节性银屑病的发病率，使用Cox回归风险模型和Kaplan-Meier估计进行分析。
结果：该研究包括使用IL-23抑制剂（n=2,273）和IL-12/23抑制剂（n=2,995）治疗的患者的配对队列。Cox回归分析显示，IL-23i和IL-12/23i队列之间的关节性银屑病累积发生率没有显着差异（p=0.812）。Kaplan-Meier估计证实，在研究期间，两个队列中关节炎性银屑病的累积发病率相似。
结论：需要长期随访研究来了解更多这些白介素抑制剂的作用。
结论：在使用IL-23抑制剂治疗的PsO患者中，与使用IL-12/23抑制剂相比，PsA的风险没有显着差异，但在数值上更低。强调了它们在PsO管理和随访中的可比疗效。
目的：本研究评估了与IL-12/23抑制剂相比，使用IL23抑制剂治疗的患者发生银屑病关节炎的风险。
方法：这项回顾性队列研究利用了TriNetX的数据，包括被诊断为牛皮癣的成年患者。包括使用IL-23或IL-12/23抑制剂治疗的患者并且倾向评分匹配。主要结果是关节性银屑病的发病率，使用Cox回归风险模型和Kaplan-Meier估计进行分析。
结果：该研究包括使用IL-23抑制剂（n=2,273）和IL-12/23抑制剂（n=2,995）治疗的患者的配对队列。Cox回归分析显示，IL-23i和IL-12/23i队列之间的关节性银屑病累积发生率没有显着差异（p=0.812）。Kaplan-Meier估计证实，在研究期间，两个队列中关节炎性银屑病的累积发病率相似。
结论：需要长期随访研究来了解更多这些白介素抑制剂的作用。
结论：在使用IL-23抑制剂治疗的PsO患者中，与使用IL-12/23抑制剂相比，PsA的风险没有显着差异，但在数值上更低。强调了它们在PsO管理和随访中的可比疗效。
